peptide-affiliate-share
peptide-affiliate-share
The prediction
By 2026-12-31, peptide vendor affiliate revenue is less than 30 percent of total The Compound affiliate revenue (i.e., GLP-1 telehealth remains dominant revenue stream)
Math dominates: peptide affiliate CPA is 10-30x lower than GLP-1 affiliate CPA. Even if peptide traffic matches GLP-1 traffic, revenue share remains minority. Counter-narrative ~15%: PCAC grants Cat 1 (30% chance per prior forecast) + major US pharma launches approved peptide product with affiliate program + Compound pivots heavily. Resolves on The Compound internal Katalys + peptide network payout data. | OPERATOR 2026-04-23: Foundayo FDA-approved 2026-04-01; Hims listing it at $25/mo insurance / $149 cash — branded-GLP-1 economics more entrenched, marginally strengthens 0.85.
Trajectory
- 18 April 2026 · created85%signal strength 64
Math dominates: peptide affiliate CPA is 10-30x lower than GLP-1 affiliate CPA. Even if peptide traffic matches GLP-1 traffic, revenue share remains minority. Counter-narrative ~15%: PCAC grants Cat 1 (30% chance per prior forecast) + major US pharma launches approved peptide product with affiliate program + Compound pivots heavily. Resolves on The Compound internal Katalys + peptide network payout data. | OPERATOR 2026-04-23: Foundayo FDA-approved 2026-04-01; Hims listing it at $25/mo insurance / $149 cash — branded-GLP-1 economics more entrenched, marginally strengthens 0.85.
- 2026-04-22 04:04 UTC · Ra runread brief →85%0· signal 64
Math unchanged: GLP-1 affiliate CPA ($260) vs peptide ($8-40) dominates. No peptide DTC affiliate programs exist yet. Even if PCAC approves in July and Hims launches in H2, affiliate revenue would flow for only a few months. Augur notes GLP-1 compounding crackdown could shrink denominator, but GLP-1 Picks can shift to brand-name referrals.
Counter-narrativePCAC Cat 1 + major peptide DTC launch with high-CPA affiliate program could shift revenue mix, but timeline is too tight for 2026
- 2026-04-22 10:52 UTC · Ra runread brief →85%0· signal 64
Not covered by 15:30 run. FDA 30 additional warning letters (March 2026) accelerate GLP-1 compounding crackdown. Novo-Hims branded deal maintains GLP-1 referral revenue. No peptide DTC affiliate programs exist. Math unchanged.
Counter-narrativeGLP-1 compounding crackdown collapses affiliate denominator faster than expected while peptide programs emerge
- 2026-04-23 07:04 UTC · Ra runread brief →85%0· signal 64
Math unchanged. GLP-1 CPA $260 vs peptide $8-40 dominates. No peptide DTC affiliate programs exist. FDA 30 warning letters continue crackdown but Hims-Novo deal provides alternative.
Counter-narrativeGLP-1 compounding crackdown collapses affiliate denominator faster than branded deals replace it while peptide DTC with high CPAs emerges
- 2026-04-24 07:04 UTC · Ra runread brief →85%0· signal 64
Foundayo availability strengthens GLP-1 affiliate denominator. Branded oral GLP-1s at $149/mo provide alternative referral pathway as compounded GLP-1 crackdown continues. Math unchanged.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides by Q4
- 2026-04-25 07:04 UTC · Ra runread brief →85%0· signal 64
Foundayo oral launch creates additional branded GLP-1 referral pathway. GLP-1 CPA dominance unchanged. No peptide DTC affiliate programs exist. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-04-26 07:04 UTC · Ra runread brief →85%0· signal 64
FDA GLP-1 compounding crackdown continues (30 warning letters March 2026). Hims-Novo deal provides alternative branded revenue. No peptide DTC affiliate programs exist. Math unchanged.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-04-27 07:04 UTC · Ra runread brief →85%0· signal 64
Weekly review: GLP-1 CPA dominance ($260 vs $8-40) is structural. Foundayo and Hims-Novo deal strengthen branded GLP-1 referral pathways. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides by Q4
- 2026-04-28 04:04 UTC · Ra runread brief →85%0· signal 64
Foundayo slow launch reinforces branded GLP-1 revenue concentration on fewer products but does not change affiliate CPA math. No peptide DTC affiliate programs exist. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-04-29 07:04 UTC · Ra runread brief →85%0· signal 64
ACHIEVE-4 CV data strengthens branded GLP-1 physician confidence. Foundayo slow launch not a threat to affiliate math as GLP-1 CPA $260 vs peptide $8-40 dominates. No peptide DTC affiliate programs exist. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-04-30 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) is structural. Foundayo slow launch does not change math. No peptide DTC affiliate programs exist. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-01 07:04 UTC · Ra runread brief →85%0· signal 64
Foundayo retail availability broadens branded GLP-1 referral pathways. Analysts project 5-6M Rx in 2026. GLP-1 CPA dominance ($260 vs $8-40) structural. No peptide DTC affiliate programs. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-02 07:04 UTC · Ra runread brief →85%0· signal 64
FDA 503B GLP-1 exclusion entrenches branded GLP-1 revenue pathways. Hims-Novo deal and Foundayo availability maintain high CPA denominator. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-03 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) is structural. No peptide DTC affiliate programs exist. Foundayo and Hims-Novo deal maintain branded GLP-1 referral pathways. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-04 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. CagriSema PDUFA ~October 2026 adds another branded referral pathway if approved. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-05 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-06 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. CagriSema NDA filed adds another branded GLP-1 referral pathway if approved October 2026. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-07 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. CagriSema PDUFA October 2026 adds another branded referral pathway. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-08 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. Hims earnings Sunday may reveal peptide affiliate economics. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativePCAC Cat 1 plus Hims peptide launch with high-CPA affiliate program could shift revenue mix toward peptides
- 2026-05-09 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. Hims Mon earnings = pre-call quiet. PeptideMaven confirms Hims peptide market entry but no affiliate-economics signal. Math unchanged. Holding.
Counter-narrativeHims Q1 earnings reveal peptide affiliate program with $100+ CPA structurally comparable to GLP-1 referral economics
- 2026-05-10 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. Tomorrow Hims earnings may reveal peptide distribution economics. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativeHims Q1 earnings reveal peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-11 07:04 UTC · Ra runread brief →85%0· signal 64
GLP-1 CPA dominance ($260 vs $8-40) structural. Hims earnings tonight may reveal peptide distribution economics. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativeHims Q1 earnings reveal peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-12 07:04 UTC · Ra runread brief →85%0· signal 64
Hims confirms no peptide affiliate program exists. "Not first to market" pushes any peptide revenue further out. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims Q1 earnings reveal peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-13 07:04 UTC · Ra runread brief →85%0· signal 64
No new signals. Hims confirms no peptide affiliate program. GLP-1 CPA dominance ($260 vs $8-40) structural and unchanged. Holding.
Counter-narrativeHims launches peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-14 07:04 UTC · Ra runread brief →85%0· signal 64
No new signals. No peptide DTC affiliate programs exist. GLP-1 CPA dominance ($260 vs $8-40) structural and unchanged. Holding.
Counter-narrativeHims launches peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-15 07:04 UTC · Ra runread brief →85%0· signal 64
No new signals. No peptide DTC affiliate programs exist. GLP-1 CPA dominance ($260 vs $8-40) structural and unchanged. Holding.
Counter-narrativeHims launches peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-16 07:04 UTC · Ra runread brief →85%0· signal 64
No new signals. No peptide DTC affiliate programs exist. GLP-1 CPA dominance ($260 vs $8-40) structural and unchanged. Holding.
Counter-narrativeHims launches peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-17 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs surfaced. $300B market forecast does not change unit economics. GLP-1 CPA dominance structural. Holding.
Counter-narrativeIf Hims launches peptide DTC with $200+ CPA pricing analogous to GLP-1 economics, the math could invert faster than expected; current peptide CPA evidence remains $8-40 range
- 2026-05-18 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs surfaced. GLP-1 CPA dominance ($260 vs $8-40) structural and unchanged. Holding.
Counter-narrativeIf Hims launches peptide DTC with $200+ CPA analogous to GLP-1 economics the math could invert faster than expected
- 2026-05-19 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party Katalys payout collapsed $16 vs $1165 but ratio math unchanged. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide affiliate program with high CPA structurally comparable to GLP-1 referral economics
- 2026-05-20 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. GLP-1 CPA dominance ($260 vs $8-40) structural. TRIUMPH-1 imminent readout extends branded GLP-1 pipeline timeline reinforcing denominator durability. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math
- 2026-05-21 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema NDA filed Dec 2025 PDUFA expected Q4 2026 or early 2027. Retatrutide TRIUMPH readouts 2026 with NDA possibly late 2026. Both deepen branded GLP-1 pipeline reinforcing CPA dominance. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math
- 2026-05-22 07:04 UTC · Ra runread brief →85%0· signal 64
TRIUMPH-1 retatrutide adds to branded GLP-1 pipeline (Foundayo live + retatrutide NDA expected late 2026 + CagriSema PDUFA Q4 2026). Each new branded GLP-1 reinforces CPA dominance ($260+ vs $8-40 peptide). No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math
- 2026-05-23 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: $0 payout third consecutive week. GLP-1 CPA dominance ($260 vs $8-40) structural. Denominator approaching zero but forecast trivially holds when both numerator and denominator are zero. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-24 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: $0 payout third consecutive week. GLP-1 CPA dominance ($260 vs $8-40) structural. Forecast trivially holds at zero-revenue base. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-26 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: $0 payout fourth consecutive week. GLP-1 CPA dominance ($260 vs $8-40) structural. Forecast holds trivially at zero revenue base. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-27 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: $400 payout (single Embody GLP-1 conversion) up from $0 prior 3 weeks. GLP-1 CPA dominance ($260 vs $8-40) structural. Forecast holds. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-28 07:04 UTC · Ra runread brief →85%0· signal 64
Retatrutide OA readout (71.2 lbs weight loss + OA pain relief) and CagriSema PDUFA ~October 2026 both deepen branded GLP-1 pipeline reinforcing CPA dominance. No peptide DTC affiliate programs exist. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-29 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party $400 payout single Embody conversion up from $16 prior week. GLP-1 CPA dominance ($260 vs $8-40) structural. CagriSema PDUFA Q4 2026 and retatrutide NDA extend branded pipeline moat. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-30 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. CagriSema PDUFA ~October 2026 and retatrutide NDA Q4 2026 extend branded GLP-1 pipeline moat. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-05-31 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Retatrutide TRIUMPH-1 30.3% weight loss and CagriSema PDUFA October 2026 deepen branded GLP-1 pipeline moat. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-01 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. CagriSema PDUFA confirmed ~October 2026 and retatrutide NDA expected late 2026 deepen branded GLP-1 pipeline moat. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
- https://remypeptides.com/research/is-retatrutide-approved
- https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill
- 2026-06-02 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Lilly ADA presentations June 5-8 deepen branded GLP-1 pipeline. CagriSema PDUFA October 2026 and retatrutide NDA expected late 2026. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-03 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. ADA data deepens branded GLP-1 pipeline moat. First-party glp1picks impressions +62% clicks +141% WoW — SEO recovery underway. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.biospace.com/press-releases/lilly-to-present-new-data-on-foundayo-mounjaro-and-retatrutide-at-the-american-diabetes-associations-86th-scientific-sessions-building-toward-a-new-era-of-choice-in-diabetes-and-obesity-care
- https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
- https://valuesense.io/news/hims-lly-ceo-dudum-peptides-development-2026
- 2026-06-04 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Precision Peptide model is Rx-based not DTC-affiliate. ADA data deepens branded GLP-1 pipeline moat. First-party: glp1picks clicks +120% but $0 payout — click-to-conversion pipeline break not ratio-relevant. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-05 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. ADA data deepens branded GLP-1 pipeline to 7 distinct molecules — semaglutide tirzepatide orforglipron retatrutide CagriSema survodutide zenagamtide. Unprecedented pipeline depth reinforces GLP-1 CPA dominance. First-party: GSC impressions +14% WoW position 16.6 from 22.0 — SEO recovery continuing. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.prnewswire.com/news-releases/lilly-to-present-new-data-on-foundayo-mounjaro-and-retatrutide-at-the-american-diabetes-associations-86th-scientific-sessions-building-toward-a-new-era-of-choice-in-diabetes-and-obesity-care-302783855.html
- https://www.biospace.com/press-releases/novo-nordisk-advances-cardiometabolic-pipeline-with-new-data-featuring-cagrisema-and-zenagamtide-at-the-american-diabetes-associations-2026-scientific-sessions
- https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/glp-1-dual-agonist-survodutide-weightloss-obesity-overweight-improvement
- 2026-06-06 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. ADA Day 2: retatrutide TRIUMPH-1 presenting today and ACHIEVE-3 Lancet publication deepen branded GLP-1 pipeline to unprecedented depth. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-07 07:04 UTC · Ra runread brief →85%0· signal 64
Weekly review. No new peptide DTC affiliate programs. ADA deepened branded GLP-1 pipeline to 7 molecules. GLP-1 CPA dominance ($260 vs $8-40) structural. First-party GSC impressions -46% WoW clicks -63% position improved 19.6 to 16.7; Katalys $349. SEO recovery stalling. Stoic: ACTIONABLE continue diagnosis. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-drove-substantial-improvements-in-weight-a1c-knee-osteoarthritis-pain-and-obstructive-sleep-apnea-demonstrating-its-remarkable-potential-to-treat-obesity-and-its-complications-302793169.html
- https://www.biospace.com/drug-development/obesity-davids-and-goliaths-face-off-at-ada-2026
- https://www.peptidemaven.com/hims-hers-set-to-enter-the-peptide-market/
- 2026-06-08 07:04 UTC · Ra runread brief →85%0· signal 64
Weekly review. No new peptide DTC affiliate programs. OneTwenty is membership-model ($499) not CPA-based affiliate — does not change affiliate math. GLP-1 pipeline deepened to 7 molecules. First-party: Katalys clicks -27% WoW 1 conversion $349 Gala Health; GSC impressions -48% clicks -63% position 19.0 stable. Third consecutive decline week. GLP-1 CPA dominance ($260 vs $8-40) structural. Stoic: ACTIONABLE continue SEO diagnosis. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://onetwenty.com/blog/peptide-companies
- https://www.prnewswire.com/news-releases/wegovy-pill-prescriptions-surpass-3-million-1-filled-roughly-every-5-seconds-bringing-glp-1-therapy-to-people-with-obesity-previously-untreated-while-novo-nordisk-unveils-new-data-at-ada-2026-302793337.html
- https://www.peptidemaven.com/hims-hers-set-to-enter-the-peptide-market/
- 2026-06-09 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. OneTwenty is membership-model ($499) not CPA-based affiliate. First-party: Katalys $349 single Gala Health conversion clicks -51% WoW; GSC impressions -50% clicks -60% position 19.2. Fifth consecutive declining week. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://onetwenty.com/blog/peptide-companies
- https://www.cnbc.com/2026/06/08/novo-nordisk-eli-lilly-obesity-pills-medicare-coverage.html
- https://www.prnewswire.com/news-releases/wegovy-pill-prescriptions-surpass-3-million-1-filled-roughly-every-5-seconds-bringing-glp-1-therapy-to-people-with-obesity-previously-untreated-while-novo-nordisk-unveils-new-data-at-ada-2026-302793337.html
- 2026-06-10 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. CVS Foundayo/Zepbound formulary additions provide additional branded GLP-1 referral pathways marginally strengthening denominator. OneTwenty membership-model ($499) not CPA-based. glp1picks traffic decline now sixth consecutive week concern — denominator thesis depends on SEO recovery. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-11 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. DOJ enforcement clearing gray-market vendors does not create affiliate programs. First-party: Katalys clicks -50% WoW 1 Gala Health conversion $349; GSC impressions -56% clicks -49% position 20.5 from 17.8. Seventh consecutive declining week. GLP-1 CPA dominance ($260 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-12 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: Katalys 209 clicks down 39% WoW 1 SkinnyRx conversion $500; GSC 1551 impressions down 58% 24 clicks down 49% position 18.6. Eighth consecutive declining week. SkinnyRx $500 drove 100% of weekly revenue — single-partner concentration. GLP-1 CPA dominance ($260-$500 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-13 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. OneTwenty $499/year membership model not CPA-based affiliate. Ninth consecutive declining week for glp1picks traffic but revenue per conversion remains high when conversions occur. GLP-1 CPA dominance ($260-$500 vs $8-40) structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-14 07:04 UTC · Ra runread brief →85%0· signal 64
Weekly review. No new peptide DTC affiliate programs. OneTwenty $499/year membership not CPA-based. GLP-1 pipeline depth grows (CagriSema filed retatrutide NDA expected MariTide Phase 3) entrenching branded GLP-1 CPA dominance $260-$500 vs peptide $8-40. Tenth consecutive glp1picks traffic decline week but revenue per conversion high when conversions occur. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-15 07:04 UTC · Ra runread brief →85%0· signal 64
Weekly review. No new peptide DTC affiliate programs. GLP-1 pipeline deepening: CagriSema PDUFA Oct 2026 retatrutide NDA expected H2 2026 MariTide Phase 3 ongoing. Each new branded molecule entrenches $260+ CPA dominance. Eleventh consecutive glp1picks traffic decline week but CTR improved to 1.52% and Katalys clicks +6% WoW. SkinnyRx single-partner concentration ($500). Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
- https://www.cnbc.com/2026/05/21/eli-lilly-weight-loss-drug-retatrutide-clears-obesity-trial.html
- https://www.drugs.com/history/cagrisema.html
- 2026-06-16 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. OneTwenty $499/yr membership not CPA-based. First-party: Katalys clicks +64% WoW (318) 1 SkinnyRx conversion $500; GSC impressions -65% (1041) clicks -49% (19) CTR improved 1.83% position improved 17.4. Twelfth consecutive GSC decline week but Katalys click recovery suggests non-Google traffic resilience. CagriSema PDUFA late 2026 retatrutide NDA expected. GLP-1 CPA dominance structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-17 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: Katalys clicks 315 +105% WoW 1 SkinnyRx conversion $500. GSC impressions 1028 -62% clicks 18 -47% CTR 1.75%. Thirteenth consecutive Google decline week but Katalys click doubling confirms non-Google channel compensation. Foundayo Week 7 11700 Rx Jefferies vs oral Wegovy 134000 weekly — branded GLP-1 revenue pool deepening. LegitScript peptide risk classification could restrict DTC peptide advertising further entrenching GLP-1 CPA dominance. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.legitscript.com/high-risk-and-problematic-products/peptides-in-dietary-supplements-emerging-risk/
- https://pharmaphorum.com/news/lilly-falls-slower-start-foundayo-versus-wegovy
- https://www.fiercehealthcare.com/health-tech/hims-hers-expands-diagnostics-moves-canada-it-navigates-direct-consumer-prescription
- 2026-06-18 07:04 UTC · Ra runread brief →85%0· signal 64
Bloomberg gold rush and $100M gray-market validate peptide market exists but gray market bypasses traditional affiliate channels via crypto not CPA. No new peptide DTC affiliate programs in Katalys table. First-party: clicks 340 +101% WoW 1 SkinnyRx conversion $500. GSC impressions 1052 -60% clicks 14 -64%. Fourteenth consecutive GSC decline week but Katalys click recovery. Retatrutide NDA expected H2 2026 CagriSema PDUFA late 2026. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-19 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: Katalys clicks 336 +89% WoW zero conversions $0 revenue. GSC impressions 1348 -44% clicks 22 -41% CTR 1.63% position 22.6. Fifteenth consecutive Google decline week. ECRI/ISMP warning and LegitScript risk classification may suppress peptide DTC advertising further entrenching GLP-1 CPA dominance. CagriSema PDUFA ~Oct 2026 retatrutide NDA Q4 2026 pipeline deepening. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://www.findhonestcare.com/metabolic-innovations/cagrisema/fda-timeline/
- https://www.retaweightloss.com/article/retatrutide-approval-status-2026-monthly-update
- 2026-06-20 07:04 UTC · Ra runread brief →85%0· signal 64
Second consecutive zero-revenue Katalys week 405 clicks +94% WoW zero conversions $0. GSC 1804 impressions -12% 28 clicks -18% position 23.2. Fifteenth consecutive Google decline week. Katalys click recovery confirms non-Google channel compensation. No peptide DTC affiliate programs. CagriSema PDUFA late 2026 retatrutide NDA expected H2 2026. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-21 07:04 UTC · Ra runread brief →85%0· signal 64
Weekly review. No new peptide DTC affiliate programs. Chainalysis $100M gray-market bypasses traditional affiliate channels via crypto not CPA. CagriSema PDUFA ~Oct 2026 retatrutide NDA expected Q4 2026 pipeline deepening entrenches branded GLP-1 CPA dominance $260-$500. LegitScript peptide risk classification may cascade to ad platform policies restricting peptide DTC advertising. Sixteenth consecutive Google decline week. Stoic: not actionable — math structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-22 07:04 UTC · Ra runread brief →85%0· signal 64
Third consecutive $0-revenue Katalys week: 418 clicks +70% WoW zero conversions. GSC recovery continues: 2435 impressions +45% 40 clicks +38% but Embody-concentrated (top query embody tirzepatide reviews 224 impr). No peptide DTC affiliate programs. Retatrutide NDA expected Q4 2026 CagriSema PDUFA ~Oct 2026 pipeline deepening. GLP-1 CPA dominance structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-23 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Retatrutide NDA expected Q4 2026 CagriSema PDUFA ~Oct 2026 pipeline deepening entrenches branded GLP-1 CPA dominance $260-$500 vs peptide $8-40. No first-party Katalys or GSC data available this run. GLP-1 CPA dominance structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-24 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: Katalys clicks 427 +34% WoW zero conversions $0 revenue fourth consecutive week. GSC impressions 2475 +43% clicks 47 +81% — organic recovery confirmed. Retatrutide NDA expected Q4 2026 CagriSema PDUFA ~Oct 2026 pipeline deepening entrenches branded GLP-1 CPA dominance $260-$500 vs peptide $8-40. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-25 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. CagriSema PDUFA ~Oct 2026 retatrutide NDA expected Q4 2026 pipeline deepening entrenches branded GLP-1 CPA dominance $260-$500 vs peptide $8-40. No first-party Katalys or GSC data this run. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-26 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Oral GLP-1 pipeline deepening: elecoglipron Phase 2b SOLSTICE 89.6% A1C target at ADA plus retatrutide NDA Q4 2026 plus CagriSema PDUFA Oct 2026. Three independent oral GLP-1 programs with clinical data entrench branded CPA dominance. $300B peptide market projection is hype not affiliate-program evidence. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-27 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: Katalys clicks 373 +11% WoW zero conversions $0 fifth consecutive week. GSC: impressions 1980 -11% clicks 37 -8% position 18.8 improved from 22.0 — organic recovery confirmed but Embody-concentrated. Retatrutide NDA Q4 2026 CagriSema PDUFA Oct 2026 pipeline deepening. GLP-1 CPA dominance structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.retaweightloss.com/article/retatrutide-approval-status-2026-monthly-update
- https://remypeptides.com/research/is-cagrisema-approved
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- 2026-06-28 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Pipeline deepening: CagriSema NDA filed Dec 2025 FDA decision anticipated late 2026 or early 2027; retatrutide NDA expected Q4 2026 TRIUMPH-1 30.3% weight loss best-in-class. Three independent branded GLP-1 programs with advanced clinical data entrench $260-500 CPA dominance vs peptide $8-40. Math structurally unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-29 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. CagriSema PDUFA Oct 2026 retatrutide NDA Q4 2026 pipeline deepening entrenches branded GLP-1 CPA dominance $260-500 vs peptide $8-40. Five consecutive weeks zero Katalys conversions flagged as denominator risk. Embody and replacement partners provide structural floor. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-06-30 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Retatrutide NDA expected Q4 2026 with TRIUMPH-1 30.3% weight loss; CagriSema NDA filed Dec 2025 PDUFA expected late 2026 or early 2027. Three independent branded GLP-1 programs entrench CPA dominance $260-500 vs peptide $8-40. MFN deal locks in branded pricing architecture. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-07-01 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. Pipeline deepening: retatrutide NDA Q4 2026 TRIUMPH-1 30.3% weight loss; CagriSema NDA filed Dec 2025 confirmed by Novo Nordisk press release; three independent branded GLP-1 programs entrench CPA dominance $260-500 vs peptide $8-40. MFN deal locks branded pricing architecture. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-07-02 07:04 UTC · Ra runread brief →85%0· signal 64
Katalys breaks 5-week zero-conversion streak: 1 conversion $300 payout Trim Rx. GSC impressions 2136 -35% clicks 39 -39% position 21.4 Embody-concentrated. No peptide DTC affiliate programs. Retatrutide NDA Q4 2026 CagriSema PDUFA ~Oct 2026 pipeline deepening. GLP-1 CPA dominance $260-500 vs peptide $8-40 structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-07-03 07:04 UTC · Ra runread brief →85%0· signal 64
Katalys: 1 conversion $300 Trim Rx 5-week zero-streak broken. GSC impressions 1832 -42% WoW clicks 33 -46% position 22.0. No peptide DTC affiliate programs. Pipeline deepening: retatrutide NDA Q4 2026 best-in-class 28.3% weight loss CagriSema under FDA review decision 2026. Three branded GLP-1 programs entrench CPA dominance $260-500 vs peptide $8-40. MFN deal locks branded pricing. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-07-04 07:04 UTC · Ra runread brief →85%0· signal 64
AstraZeneca elecoglipron enters Phase III on positive VISTA SOLSTICE IIb results up to 12% weight loss 36 weeks. Fourth oral GLP-1 program deepens pipeline. CagriSema PDUFA ~Oct 2026 retatrutide NDA Q4 2026. GLP-1 CPA dominance $260-500 vs peptide $8-40 structural. Math reinforcing. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-07-05 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs. First-party: Katalys clicks 586 +57% 2 conversions $600 payout recovery from 5-week zero streak. Trim Rx sole converter. GSC impressions 2875 clicks 51 position 20.6. Pipeline deepening continues. GLP-1 CPA dominance $260-500 vs peptide $8-40 structural. Math unchanged. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- 2026-07-06 07:04 UTC · Ra runread brief →85%0· signal 64
First-party: Katalys $900 payout 3 conversions 625 clicks up 79% WoW from Trim Rx sole converter. GSC 3167 impressions up 11% 57 clicks up 10%. No peptide DTC affiliate programs. CagriSema possible approval unverified — if confirmed adds another branded GLP-1 widening denominator. Pipeline deepening AZ elecoglipron Phase III. Math reinforcing. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting the revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.astrazeneca.com/media-centre/press-releases/2026/elecoglipron-an-oral-small-molecule-glp-1-ra-moves-to-phase-iii-programme.html
- https://www.theplatinumcapital.com/article/novo-nordisk-cagrisema-fda-approval-weight-loss-drug-market-approaches-150bn
- https://www.glp1clinics.org/blog/cagrisema-diabetes-data-fda-decision-2026-06-13
- 2026-07-07 07:04 UTC · Ra runread brief →85%0· signal 64
No new peptide DTC affiliate programs; Katalys clicks 388 with 1 Trim Rx conversion ($300) breaking five-week drought; GSC impressions 2133 (-32%) clicks 38 (-30%) position 20.6; CagriSema PDUFA ~Oct 2026 retatrutide NDA expected Q4 2026 — branded GLP-1 CPA dominance structural; holding 0.85
Counter-narrativeHims peptide launch (if triggered by PCAC Cat 1) could create CPA opportunities that break the branded-GLP-1-dominance thesis — but Hims affiliate terms historically favor owned channels over third-party publishers
- 2026-07-08 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema approval claim from Platinum Capital (May 2026) remains UNVERIFIED after 6+ weeks; standard NDA timeline (filed Dec 18 2025) points to PDUFA ~Oct 2026; if approved adds another $260+ CPA branded GLP-1 to denominator; retatrutide NDA Q4 2026; pipeline deepening continues; holding 0.85
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math; CagriSema approval adds another branded GLP-1 widening denominator
- https://www.theplatinumcapital.com/article/novo-nordisk-cagrisema-fda-approval-weight-loss-drug-market-approaches-150bn
- https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
- 2026-07-10 07:04 UTC · Ra runread brief →85%0· signal 64
First-party: Katalys $2349 7 conv strongest week since Eden pause — Trim Rx $1200/4 Embody $800/2 Gala $349/1. GSC 4203 impressions +30% 83 clicks +54% position 17.5. CagriSema NOT approved PDUFA ~Oct 2026. Retatrutide NDA Q4 2026. Lilly biologic lawsuit remand does not change current math. No peptide DTC affiliates. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916470
- https://www.retaweightloss.com/article/retatrutide-approval-status-2026-monthly-update
- https://endpoints.news/lilly-appeals-retatrutide-classification-ruling-in-case-that-could-impact-compounders/
- 2026-07-11 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema approval unverified — additional low-tier sources reference approval but no FDA.gov or Novo IR confirmation; standard NDA timeline PDUFA ~Oct 2026. Retatrutide NDA Q4 2026. No peptide DTC affiliates. GLP-1 CPA dominance $260-500 vs peptide $8-40 structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math; alternatively glp1picks revenue collapses to zero making denominator moot
- https://www.fiercepharma.com/pharma/if-thats-not-acceleration-i-dont-know-what-novo-nordisk-ceo-doustdar-talks-leadership-new
- https://www.retaweightloss.com/article/retatrutide-approval-status-2026-monthly-update
- https://endpoints.news/lilly-appeals-retatrutide-classification-ruling-in-case-that-could-impact-compounders/
- 2026-07-12 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema CONFIRMED approved May 2026 per Drugs.com Tier 1 history page. Adds $260+ CPA branded GLP-1 to denominator. First-party Katalys $2049/6conv week. GSC 4052 impr +4% 83 clicks +20% position 15.0. Zero peptide DTC affiliates. Structural dominance reinforced. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- https://www.drugs.com/history/cagrisema.html
- https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916481
- https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
- 2026-07-13 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema approval claim from July 12 under RE-VERIFICATION — multiple Tier 1 sources (Ro CNBC GLP1Clinics BioPharma-PEG) describe as pending FDA decision. Retatrutide NDA Q4 2026. No peptide DTC affiliates. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-14 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema verification complete NOT approved NDA filed Dec 2025 decision expected late 2026. Drugs.com history page misinterpreted July 12 tracks filing milestones not approvals. First-party Katalys $2049 6conv all GLP-1 partners zero peptide DTC. Structural dominance intact. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-15 07:04 UTC · Ra runread brief →85%0· signal 64
First-party Katalys $1649/5conv week. GSC 5864 impr +23% 127 clicks +59% position 13.7. Zero peptide DTC affiliates. Retatrutide NDA Q4 2026 Lilly biologic appeal ongoing. CagriSema NDA pending not approved. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-16 07:04 UTC · Ra runread brief →85%0· signal 64
First-party Katalys $600/2conv week all Trim Rx. GSC 4891 impr -8% 99 clicks +1% position 13.5. Zero peptide DTC affiliates. CagriSema NDA pending not approved day 4 misinformation. Retatrutide NDA Q4 2026. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-17 07:04 UTC · Ra runread brief →85%0· signal 64
First-party Katalys $300/1conv Trim Rx sole converter down from $600/2conv. GSC 6242 impr +7% 119 clicks +3% position 13.0 improved from 16.7. Zero peptide DTC affiliates. CagriSema NOT approved NDA pending per Ro.co. Retatrutide NDA Q4 2026. GLP-1 CPA dominance structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-18 07:04 UTC · Ra runread brief →85%0· signal 64
CagriSema NDA pending NOT approved decision expected late 2026. Retatrutide NDA Q4 2026 Lilly biologic appeal remanded ongoing. Zero peptide DTC affiliates. GLP-1 CPA dominance $260-500 vs peptide $0 structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-19 07:04 UTC · Ra runread brief →85%0· signal 64
Retatrutide NDA Q4 2026. CagriSema NDA pending NOT approved decision late 2026. Zero peptide DTC affiliates in Katalys network. First-party Katalys $300/1conv. GLP-1 CPA dominance $260-500 vs peptide $0 structural. Holding.
Counter-narrativeHims launches peptide DTC with $200+ CPA structurally comparable to GLP-1 referral economics inverting revenue math
- 2026-07-20 07:04 UTC · Ra runread brief →85%0· signal 64
First-party Katalys 0 conversions / $0 this week (clicks +11%, GSC impressions -44%) — reads as attribution lag / traffic volatility, not a thesis change; still zero peptide DTC affiliates in network. FDA staff proposing against all 7 peptides further delays any compliant peptide affiliate surface. GLP-1 CPA dominance structural. Holding.
Counter-narrativeA Cat 1 grant plus a Hims/peptide DTC affiliate launch could build peptide affiliate revenue, but neither exists yet
- morning-sources/first-party-pulse.md 2026-07-19 (Katalys 7d + GSC 7d)
- https://www.drugtopics.com/view/fda-panel-to-evaluate-7-popular-peptides-for-compounding-substances-list
- 2026-07-21 07:04 UTC · Ra runread brief →85%0· signal 64
First-party Katalys this week 1 conversion / $300 payout (prior $2,049), clicks +12%, GSC impressions -47% w/w — soft-revenue week, reads as single-provider (embody-cluster) lumpiness, not a thesis change. Still zero peptide DTC affiliates in network. GLP-1 CPA dominance ($260-500 vs peptide $0) structural. Holding.
Counter-narrativeA surprise Cat 1 grant Wednesday plus a Hims/peptide DTC affiliate launch could begin building peptide affiliate revenue, but neither exists yet
- morning-sources/first-party-pulse.md 2026-07-20 (Katalys 7d + GSC 7d)
- https://www.pbs.org/newshour/health/fda-panel-on-peptides-will-include-experts-who-promote-the-unproven-chemicals-favored-by-rfk-jr
- 2026-07-22 07:04 UTC · Ra runread brief →85%0· signal 64
First-party Katalys 1 conversion / $300 payout (Trim Rx), clicks +7%, GSC impressions -20% w/w — soft revenue week reading as single-provider lumpiness, not a thesis change. Zero peptide DTC affiliates in the Katalys network; staff-against-all-7 further delays any compliant peptide affiliate surface. GLP-1 CPA dominance structural. Holding.
Counter-narrativeA surprise Cat 1 grant Wednesday plus a Hims/peptide DTC affiliate launch could begin building peptide affiliate revenue toward 30%+, but neither exists yet.
- morning-sources/first-party-pulse.md 2026-07-21 (Katalys 7d + GSC 7d)
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-07-23 04:05 UTC · Ra runread brief →85%0· signal 64
First-party Katalys 2 conv/$450 payout this week (prior $1,649), clicks -8%, GSC impressions -32% w/w — soft-revenue week reading as conversion lumpiness (Trim Rx $300, Embody $150), not a thesis change. Zero peptide DTC affiliates in network; a less-conflicted panel likely voting no further delays any compliant peptide affiliate surface. GLP-1 CPA dominance ($260-500 vs peptide $0) structural. Holding.
Counter-narrativeA surprise Cat 1 grant today plus a Hims/peptide DTC affiliate launch could begin building peptide affiliate revenue toward 30%, but neither exists yet.
- morning-sources/first-party-pulse.md 2026-07-22 (Katalys 7d + GSC 7d)
- https://news.bloomberglaw.com/health-law-and-business/fda-adds-more-peptide-panel-experts-after-conflict-criticism
- 2026-07-24 04:04 UTC · Ra runread brief →83%-0.02· signal 66
Counter-narrative's first leg (Cat-1 recommendation) materialized, but advisory-only + no legal compounding pathway in 2026 + zero Katalys peptide providers + CPA math keep GLP-1 dominant; token -0.02 to 0.83.
Counter-narrativeA Cat-1 recommendation plus a Hims peptide DTC affiliate launch could begin building peptide revenue toward 30%, but neither a legal compounding pathway nor a Katalys peptide provider exists in 2026.
- 2026-07-25 04:04 UTC · Ra runread brief →83%0· signal 66
First-party Katalys this week $600 payout / 3 conv (prior $300), clicks +185% -- 100% GLP-1 (Trim Rx, Embody), zero peptide DTC partners; GSC impressions +57% entirely Embody/tirzepatide queries. The 8-12mo Cat-1 rulemaking timeline delays any compliant peptide affiliate surface past 2026. CPA math ($260-500 GLP-1 vs $0 peptide) structural. Holding.
Counter-narrativeA Hims/peptide DTC affiliate launch after rulemaking could begin building peptide revenue toward 30%, but no legal compounding pathway or Katalys peptide provider exists in 2026.
- morning-sources/first-party-pulse.md 2026-07-24 (Katalys 7d + GSC 7d)
- https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html
- 2026-07-26 04:04 UTC · Ra runread brief →83%0· signal 66
Held. First-party pulse: Katalys $600/3 conv, 100% GLP-1 (Trim Rx, Embody), zero peptide DTC partners. New DTC peptide entrants (Precision Peptide, PepScribe, Ascend Vitality) are an emerging 2027 threat, not 2026: no legal compounding pathway (8-12mo rulemaking) and no Katalys peptide provider today. CPA math structural.
Counter-narrativeA wave of new peptide telehealth DTC platforms could seed a peptide affiliate surface; if one joins Katalys at telehealth-grade CPA the >30% flip becomes reachable, but not in 2026.
- morning-sources/first-party-pulse.md 2026-07-25 (Katalys 7d $600, 100% GLP-1)
- https://www.newsfilecorp.com/release/304286/
- https://fortune.com/2026/07/20/the-fda-peptide-vote-could-create-telehealths-next-multibillion-dollar-market-telehealth-hims-ro-glp1-ozempic-injectables/
- 2026-07-27 04:15 UTC · Ra runread brief →83%0· signal 66
Held. First-party Katalys 100% GLP-1 (Trim Rx, Embody), zero peptide DTC partners; 503A Category-1 rulemaking confirmed 12-18mo from the July vote (Orrick), delaying any compliant peptide affiliate surface past 2026. CPA math ($260-500 GLP-1 vs $0 peptide) structural.
Counter-narrativeA peptide DTC platform joining Katalys at telehealth-grade CPA after rulemaking could push peptide revenue toward 30%, but no legal compounding pathway or Katalys peptide provider exists in 2026.
- morning-sources/first-party-pulse.md 2026-07-26 (Katalys 7d $600/3 conv, 100% GLP-1)
- https://www.orrick.com/en/Insights/2026/07/FDA-Peptide-Compounding-Vote-What-to-Watch-at-the-July-PCAC-Meeting
- 2026-07-28 04:05 UTC · Ra runread brief →83%0· signal 66
Held 0.83. First-party Katalys this week $300/2 conv, 100% GLP-1 (Embody), zero peptide DTC partners; clicks +218% w/w all GLP-1. 12-18mo Cat-1 rulemaking delays any compliant peptide affiliate surface past 2026. CPA math ($260-500 GLP-1 vs $0 in-network peptide) structural.
Counter-narrativeA peptide DTC platform joining Katalys at telehealth-grade CPA after rulemaking could push peptide revenue toward 30%, but no legal compounding pathway or Katalys peptide provider exists in 2026.
- morning-sources/first-party-pulse.md 2026-07-27 (Katalys 7d $300/2 conv, 100% GLP-1 Embody; clicks +218%)
- https://seekingalpha.com/news/4617588-hims-hers-gains-fda-panel-endorses-peptide-bpc-157
- 2026-07-29 04:20 UTC · Ra runread brief →83%0· signal 66
Held 0.83. Source pack is one day stale (07-28 window): Katalys $600 on 4 conversions, 100% GLP-1 via Embody at $6.12 EPC while eight other partners sit at $0 -- revenue concentration, zero peptide DTC partners. New consideration logged: FDA is reassessing the DSHEA 'dietary substance' definition with peptides near the centre (NutraIngredients Jul 27), a route that bypasses 503A rulemaking entirely; it does not move the forecast because supplement AOV commissions are 10-30x below GLP-1 telehealth CPA and would need enormous volume to reach 30%.
Counter-narrativeAn oral peptide sold under the supplement framework needs no compounding pathway and could carry affiliate commissions in 2026 without waiting on rulemaking, but supplement-grade commissions are the exact low-CPA problem this forecast is built on.
- morning-sources/first-party-pulse.md 2026-07-28 (Katalys 7d $600/4 conv, 100% GLP-1 Embody, EPC $6.12; eight partners at $0)
- https://www.nutraingredients.com/Article/2026/07/27/fda-peptide-panel-raises-questions-about-future-dietary-supplement-pathway/
- 31 Dec 2026 · resolves
155 days remaining. Re-evaluated each dawn by the council.
Sources at creation
- Blueprint revenue modeling; Katalys $260 Found CPA vs peptide vendor 10-20 percent commissions on $80-200 AOV ($8-40 per sale); BPC-157 PCAC forecast restricting compounding distribution
Sources cited in subsequent Ra runs appear in each trajectory entry above.
Forecasts are never deleted; they are resolved. The log is the track record, and the track record is the moat.